Vital

Peptides

KLOW Peptide Blend: GHK-Cu, TB-500, BPC-157, KPV

KLOW is a premixed vial of GHK-Cu, TB-500, BPC-157 and KPV. Learn what each part is, how thin the human evidence is, how KLOW differs from GLOW, and how to check a source.

Last reviewed

The Vital angle

Vital can save a blend such as KLOW as a stack with the mass of each part and the diluent volume. When you log a draw in syringe units, Vital shows the amount of each part in that draw, and the dose log keeps the site, any symptoms and a severity. Vital is a tracking tool and does not suggest a dose.

What the KLOW peptide blend is

The KLOW peptide blend is a single vial that sellers fill with four separate peptides: GHK-Cu, TB-500, BPC-157 and KPV. The name comes from the first letters of those parts. It is sold as a lyophilized (freeze-dried) powder that a user mixes with a diluent before injection. Seller listings often describe a total of about 80 mg of peptide per vial, with GHK-Cu as the largest part by mass, but the amounts change from one seller to the next.

KLOW is not an FDA-approved drug, and none of its four parts is an FDA-approved drug. No company makes it to a drug label. It comes from research-chemical sellers or, in some cases, from compounders. This guide explains what is in the vial, what the research does and does not show, and how to check what you have. It does not recommend a dose, a schedule or a cycle for KLOW or for any of its parts.

The four parts of the blend

Each part of KLOW has its own research history. Most of that research is in cells and animals.

  • BPC-157 is a 15-amino-acid peptide based on a sequence in human gastric juice. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine found strong preclinical signals for tissue repair, but only three small human pilot studies. The authors say BPC-157 is investigational and its use needs caution.
  • TB-500 is a short synthetic fragment linked to thymosin beta-4, a natural protein. The FDA says it has not identified any human exposure data for the fragment.
  • GHK-Cu is a copper-binding tripeptide found in human plasma. Most human studies use it in topical skin creams. The FDA notes limited human data for injectable routes.
  • KPV is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone. Mouse studies of colitis showed less inflammation. The FDA says it has not identified human exposure data on drug products that contain KPV.

The evidence for each part is mostly preclinical. No published controlled trial tests the four-part KLOW blend in people. For more on two of these parts together, see the BPC-157 and TB-500 stack guide.

KLOW vs GLOW

Sellers use the name GLOW for a three-part blend of BPC-157, TB-500 and GHK-Cu. KLOW is the same mix plus KPV. The difference sounds small, but it has two effects:

  1. A fourth peptide adds a fourth set of identity, purity and sterility questions.
  2. With four parts in one vial, you cannot connect a side effect to one part. If a rash, a headache or a site reaction starts, the vial gives no clue which part caused it.

Neither blend has a drug label. A blend name is a sales name, not a standard formula. Two vials sold as "KLOW" can hold different masses or a different ratio. Read the label and the certificate of analysis for the exact vial you have.

Regulatory status in 2026

The FDA keeps a page on bulk drug substances for compounding that may present significant safety risks. On the version current as of April 22, 2026, BPC-157, the TB-500 fragment, KPV, and GHK-Cu for injectable routes all appear in a table of nominations that were withdrawn. The FDA entries note a possible immunogenicity risk for BPC-157, the TB-500 fragment and injected GHK-Cu, and little or no human safety data for all four.

A move to that table is not an FDA approval and not a finding of safety. None of these peptides is an FDA-approved drug. Products labeled "for research use only" are not made or checked as drugs for human use. On July 23 and 24, 2026, an FDA advisory committee voted to recommend BPC-157, TB-500 and KPV for the list of bulk substances that pharmacies can compound, against the advice of FDA staff. GHK-Cu was not part of that vote. The votes do not bind the FDA, and pharmacies cannot compound these peptides under that list until rulemaking is final. Check the FDA page for the current position, because it changes.

For athletes, the World Anti-Doping Agency (WADA) prohibits BPC-157 under section S0 and thymosin beta-4 and its derivatives, such as TB-500, under section S2. USADA's advisory on the 2027 list says both stay prohibited. A KLOW vial contains both.

How reconstitution math works for a blend

A blend changes the arithmetic. When you mix one vial, every draw from it contains all four parts in a fixed ratio. You cannot change one part without changing all of them.

The example below is a math example only. The numbers are hypothetical and round. They are not a dose and not a suggestion for KLOW.

  1. Assume a hypothetical vial holds 20 mg of peptide A and 2 mg of peptide B.
  2. Assume it is mixed with 2 mL of diluent. Peptide A is then 10 mg per mL, and peptide B is 1 mg per mL.
  3. On a U-100 insulin syringe, 100 units equal 1 mL, so 10 units equal 0.1 mL.
  4. A 10-unit draw then holds 1 mg of A and 0.1 mg of B.

The same draw always carries the same ratio. For a step-by-step look at mixing, see how to reconstitute peptides with BAC water, and for syringe markings, see U-40 vs U-100 syringes. Confirm every draw with your prescriber or pharmacist before you inject.

How to check a KLOW source

Most KLOW vials come from sellers outside the licensed pharmacy system. That makes the source check the most important step. A full method is in how to check a peptide catalog source.

  1. Find the mass of each part on the vial label, not only the total.
  2. Ask for a certificate of analysis for the exact lot number. Check that it names a testing lab and a date.
  3. Make sure the certificate reports identity and purity for each of the four parts, not for the blend as one number.
  4. Look for sterility and endotoxin results. A purity result does not show that a vial is sterile.
  5. Treat "for research use only" next to human dosing advice as a red flag.
  6. Write down the lot number and the seller before the first use.

Storage also matters. Mixed peptides can lose strength or grow bacteria. See compounded GLP-1 vial storage for general vial handling.

Warning signs that need care

Because the long-term human safety of every part is unknown, watch for changes after each injection.

  • Get medical care right away for a hot, red, spreading or very painful injection site, a lump that grows, or fever.
  • Get medical care for a severe headache, vision changes, chest pain or a fast heartbeat.
  • Get emergency care for swelling of the face, lips, tongue or throat, hives over the body, or trouble breathing.

Milder site reactions are covered in peptide injection site reactions. Tell every clinician you see that you use KLOW, and name all four parts.

Keeping a record for a blend

A record cannot make a blend safer. It can give a clinician a timeline if a problem starts.

  1. Record the blend name, the seller, the lot number and the mass of each part.
  2. Record the diluent volume and the date you mixed the vial.
  3. Log each draw in syringe units, with the date, time and injection site.
  4. Note new symptoms on the day they start, with a severity.
  5. Keep a list of other medications and supplements, with start and stop dates.

Bring this record to each appointment. A dose log for a doctor visit shows one way to organize it.

Free toolPeptide reconstitution calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Four unapproved peptides in one vial

    BPC-157, TB-500, GHK-Cu and KPV are not FDA-approved drugs. A blend adds four separate identity, purity and sterility risks, and no controlled human trial has tested the combination.

  • A fixed ratio that cannot be split

    Every draw from a mixed blend carries all four parts in the same ratio. You cannot change one part without changing the others, and you cannot tell which part caused a side effect.

  • Injected GHK-Cu

    Most human research on GHK-Cu uses topical skin products. The FDA notes limited human data for injectable routes.

  • "For research use only" vials

    These products are not made or checked as drugs for human use. Ask for a lot-specific certificate of analysis that reports each part, plus sterility and endotoxin results.

  • Competitive sport

    WADA prohibits BPC-157 (S0) and thymosin beta-4 derivatives such as TB-500 (S2) at all times. A KLOW vial contains both.

Frequently asked questions

  • KLOW is a premixed vial of four peptides: GHK-Cu, TB-500, BPC-157 and KPV. Seller listings often describe about 80 mg in total, with GHK-Cu as the largest part, but amounts change between sellers. Read the label and the certificate of analysis for your vial.

  • GLOW is a three-part blend of BPC-157, TB-500 and GHK-Cu. KLOW adds KPV. The extra part adds another set of purity and sterility questions and makes it harder to connect a side effect to one part.

  • No. KLOW is not an FDA-approved drug, and none of its four parts is an FDA-approved drug. A July 2026 FDA advisory committee vote on three of the parts is a non-binding recommendation about compounding, not an approval or a finding of safety.

  • No controlled human trial has tested the KLOW blend. BPC-157 has three small human pilot studies. The FDA reports no identified human exposure data for TB-500 or KPV drug products and limited human data for injected GHK-Cu.

  • No. After mixing, every draw holds all four parts in a fixed ratio. A larger or smaller draw changes all of them together. Ask your prescriber or pharmacist to confirm any draw.

  • KLOW contains BPC-157, which WADA prohibits under S0, and TB-500, which WADA prohibits under S2 as a thymosin beta-4 derivative. Athletes subject to testing cannot use it at any time.

Sources

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
  2. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing · Current Reviews in Musculoskeletal Medicine (Springer)
  3. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data · NIH / NCBI
  4. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease · NIH / PubMed
  5. Athlete Advisory: What's New on the 2027 WADA Prohibited List? · U.S. Anti-Doping Agency
  6. FDA advisory committee nominates six peptides for pharmacies to compound · National Community Pharmacists Association

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.